Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059787 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00059787: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00059787 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059787, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2003-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059787
The ClinicalTrials.gov registry entry for NCT00059787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00059787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059787 about?
NCT00059787 is a clinical study titled "Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma". This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such as erlotinib may interfere with ...
What is the current status of trial NCT00059787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2003-04. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00059787?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT00059787?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.